Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized open-label study of sapablursen (ISIS 702843) in phlebotomy-dependent polycythemia vera
2024-512482-14-00Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2024
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of sapablursen in polycythemia vera (PV), sponsored by Ionis Pharmaceuticals. Primary endpoint: Reduction in phlebotomy frequency during treatment period. Started Jul 2024; status: completed.
02
Drugs
sapablursen
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2024-512482-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512482-14-00.